Congress Platform

ESMO events

ESMO Immuno-Oncology Congress 2021

topics

Cancer Immunology and Immunotherapy Lung and other thoracic tumours Head and neck cancers Translational research

Date

Reset

Search results (13)

Cancer Immunology and Immunotherapy

8 Dec 2021

How much is enough with immunotherapy?

Immunotherapy: from initial scepticism to the heart of cancer treatment

Cancer Immunology and Immunotherapy

8 Dec 2021

Immunotherapy: from initial scepticism to the heart of cancer treatment

Cancer Immunology and Immunotherapy

8 Dec 2021

Tumour mutational burden as a number – is it predictive enough?

Cancer Immunology and Immunotherapy

8 Dec 2021

Survival benefits of pembrolizumab plus chemotherapy are confirmed in East-Asian patients with advanced NSCLC

Cancer Immunology and Immunotherapy

10 Dec 2021

A new immunotherapy-based combination is promising in nasopharyngeal cancer

Cancer Immunology and Immunotherapy

8 Dec 2021

Which biomarkers and how many should we use to improve outcomes with immunotherapy?

The complexity of identifying and clinically validating immunotherapy biomarkers can be addressed by broadening tumour sampling and expanding the characterisation methodologies used

By Samra Turajlic

Cancer Immunology and Immunotherapy

8 Dec 2021

New immunotherapies are explored to improve the treatment of solid tumours

Cancer Immunology and Immunotherapy

9 Dec 2021

Are amplifying RNA vaccines the way forward for CAR-T-cell therapy?

Cancer Immunology and Immunotherapy

10 Dec 2021

Biomarkers for immunotherapy: where are we?

The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution

By Andrew J.S. Furness

Cancer Immunology and Immunotherapy

9 Dec 2021

Can ctDNA changes after neoadjuvant therapy inform management of early NSCLC?

1 of 2
2

Daily Reporter

Twitter
Facebook
Youtube
RSS
LinkedIn
Instagram

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano – CH

Home
Editorial Board
All Editions

Privacy Policy
ESMO Website

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

Necessary cookies
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.